---
figid: PMC4571765__z9k0141532820003
figtitle: Working model of convergent pLTF pathways
organisms:
- Rattus norvegicus
- Homo sapiens
organisms_ner:
- Homo sapiens
- Rattus norvegicus
- Drosophila melanogaster
pmcid: PMC4571765
filename: z9k0141532820003.jpg
figlink: /pmc/articles/PMC4571765/figure/F3/
number: F3
caption: Working model of convergent pLTF pathways. The Q pathway to phrenic motor
  facilitation (pMF) is initiated by episodic activation of Gq protein-coupled 5-HT2
  receptors (; ) followed by PKCθ activation (), new brain-derived neurotrophic factor
  (BDNF) synthesis (), TrkB (; Dale EA and Mitchell GS, unpublished observations),
  and ERK/MAP kinase activation (Hoffman et al. 2012). The mechanism whereby ERK elicits
  pLTF remains unknown. We propose a newly organized “S” pathway (right) to pLTF initiated
  by adenosine 2A (A2A) receptors (), followed by cAMP production, EPAC, Akt, and
  mTOR activation () and new synthesis of immature TrkB isoforms (). Mechanisms downstream
  of iTrkB are unknown. S-to-Q pathway inhibition via PKA (Hoffman and Mitchell 2013)
  diverges at cAMP based on recent observations ().
papertitle: Mammalian target of rapamycin is required for phrenic long-term facilitation
  following severe but not moderate acute intermittent hypoxia.
reftext: Brendan J. Dougherty, et al. J Neurophysiol. 2015 Sep;114(3):1784-1791.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9742616
figid_alias: PMC4571765__F3
figtype: Figure
redirect_from: /figures/PMC4571765__F3
ndex: da600808-dea8-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4571765__z9k0141532820003.html
  '@type': Dataset
  description: Working model of convergent pLTF pathways. The Q pathway to phrenic
    motor facilitation (pMF) is initiated by episodic activation of Gq protein-coupled
    5-HT2 receptors (; ) followed by PKCθ activation (), new brain-derived neurotrophic
    factor (BDNF) synthesis (), TrkB (; Dale EA and Mitchell GS, unpublished observations),
    and ERK/MAP kinase activation (Hoffman et al. 2012). The mechanism whereby ERK
    elicits pLTF remains unknown. We propose a newly organized “S” pathway (right)
    to pLTF initiated by adenosine 2A (A2A) receptors (), followed by cAMP production,
    EPAC, Akt, and mTOR activation () and new synthesis of immature TrkB isoforms
    (). Mechanisms downstream of iTrkB are unknown. S-to-Q pathway inhibition via
    PKA (Hoffman and Mitchell 2013) diverges at cAMP based on recent observations
    ().
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IGKV2D-29
  - HTR7
  - GNAS
  - GNAL
  - RAPGEF3
  - RAPGEF4
  - BDNF
  - BDNF-AS
  - EPHB2
  - MAPK1
  - MAPK3
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - RPTOR
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - Htr2a
  - Sptan1
  - Htr7
  - Rapgef3
  - Bdnf
  - Ephb1
  - Prkcg
  - Akt1
  - 5-HT2A
  - 5-HT7
  - gs
  - Epac
  - Erk7
  - rl
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - Akt
  - Crtc
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - 5-HT
  - Glutamate
  - Cancer
---
